All Day Stocks

[Snowie]

$BLQC ~ BlockQuarry Announces Acquisition of Blockchain Energy Services, LLC, a Subsidiary of Pantheon Resources, Inc.
https://www.globenewswire.com/news-release/2023/05/04/2661443/0/en/BlockQuarry-Announces-Acquisition-of-Blockchain-Energy-Services-LLC-a-Subsidiary-of-Pantheon-Resources-Inc.html

In connection with this agreement, the Company entered into a strategic partnership agreement with Pantheon whereby the Company will fund and develop the infrastructure needed to make the data processing site operational, with Pantheon providing operational and engineering expertise. The partnership has an initial term of 12 months and is thereafter cancelable by either party with 90 days’ notice. The Company will pay 10% of all revenues from the mining site to Pantheon as consideration for the agreement.

[budfoxfun]

$CBGL (OTC PINK: CBGL), a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, and KRTL International Corp., today announced, an exclusive distribution agreement for Huella Singani in California. Under the terms of the agreement, CBGL will partner with KRTL to be the exclusive distributor of Huella Singani in California.

KRTL International Corp., a wholly owned subsidiary of KRTL Holding Group, Inc. (OTC PINK: KRTL), has entered into an exclusive distribution agreement in which KRTL International Corp. can license a uniquely exclusive drink from Bolivia, Huella Singani. The territories include United States, Canada, Mexico, Colombia, Dominican Republic, and Jamaica.

Singani is a Bolivian spirit distilled from white Muscat of the Alexandria grapes grown in the Bolivian Andes. It is the country’s national distilled spirit and is considered part of its cultural patrimony. Huella is the first singani company in Bolivia to have successfully infused a non-psychoactive extract of the coca leaf into singani. Coca extract has been shown to have a variety of health benefits, including improved cognitive function, increased energy levels, and reduced inflammation. Huella Singani is committed to sustainability and nature. Huella’s process is 100% ecological down to bottles that are made from 100% recycled ecological glass.

KRTL International has fostered multiple relationships in Bolivia and has scheduled trip back to Bolivia and Chile in the month of May. We are using this trip to further our international business activity. Together with CBGL, KRTL is excited, and committed to bringing innovative beverages to the US. The company is focused on the introduction, logistics and planning process involving this commemorative event.

“CBGL has taken multiple steps in its restructuring program by cancelling significant debt without taking on additional debt or equity financing to further strengthen its position and effectively bring intrinsic value to this venture,” said Edward Manolos, CEO of Cannabis Global, Inc. “We are happy to report that the Company has maintained its current reporting with OTC Markets and is continuing in its efforts to complete the Company audit needed to once again become and SEC reporting company.”

“Huella Singani embodies a rich culture from Bolivia. We are very excited to be the first to introduce it to the North American and Caribbean markets,” said Nick Coss, Spirits Marketing & Logistics for KRTL International Corp.

About KRTL International Corp.

KRTL International Corp., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC PINK: KRTL), is an organization focused on green technology. In addition, KRTL International is a consulting and distribution company focused on technology and innovations to help greater profitability, social governance, and environmental outcomes to increase and support the 2030 Agenda. This will contribute to improved production, nutritional quality, storage stability, food security, social equity, smart cities, technological advancement for sustainability and much more.

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the OTC Markets Group, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

[budfoxfun]

$CBGL Our New Family “Botan” long expected new cannabis brand.

https://cannabisglobalinc.com/new-brand-botan/

[budfoxfun]

$CBGL Cannabis Global Completes Significant Debt Cancellations in Q1 - Over $800K in Debt Extinguishment - Actively Negotiating Additional Debt Settlements

https://feeds.issuerdirect.com/news-release.html?newsid=7256443189477382

[Robertscott]

$CBGL Some of our projects involve: hemp cultivation of up to 100 acres, unique powdered cannabis drinks product line and intellectual properties including patents and trademarks.

[budfoxfun]

$CBGL big news hitting this week: Cannabis Global and KRTL International Corp. Announce Exclusive Distribution Agreement for Huella Singani https://www.marketwatch.com/press-release/cannabis-global-and-krtl-international-corp-announce-exclusive-distribution-agreement-for-huella-singani-2023-05-02?reflink=mw_share_twitter

[budfoxfun]

$CBGL News: LOS ANGELES, May 02, 2023 (GLOBE NEWSWIRE) -- Cannabis Global, Inc. (OTC PINK: CBGL), a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, and KRTL International Corp., today announced, an exclusive distribution agreement for Huella Singani in California. Under the terms of the agreement, CBGL will partner with KRTL to be the exclusive distributor of Huella Singani in California.

KRTL International Corp., a wholly owned subsidiary of KRTL Holding Group, Inc. (OTC PINK: KRTL), has entered into an exclusive distribution agreement in which KRTL International Corp. can license a uniquely exclusive drink from Bolivia, Huella Singani. The territories include United States, Canada, Mexico, Colombia, Dominican Republic, and Jamaica.

Singani is a Bolivian spirit distilled from white Muscat of the Alexandria grapes grown in the Bolivian Andes. It is the country’s national distilled spirit and is considered part of its cultural patrimony. Huella is the first singani company in Bolivia to have successfully infused a non-psychoactive extract of the coca leaf into singani. Coca extract has been shown to have a variety of health benefits, including improved cognitive function, increased energy levels, and reduced inflammation. Huella Singani is committed to sustainability and nature. Huella’s process is 100% ecological down to bottles that are made from 100% recycled ecological glass.

KRTL International has fostered multiple relationships in Bolivia and has scheduled trip back to Bolivia and Chile in the month of May. We are using this trip to further our international business activity. Together with CBGL, KRTL is excited, and committed to bringing innovative beverages to the US. The company is focused on the introduction, logistics and planning process involving this commemorative event.

“CBGL has taken multiple steps in its restructuring program by cancelling significant debt without taking on additional debt or equity financing to further strengthen its position and effectively bring intrinsic value to this venture,” said Edward Manolos, CEO of Cannabis Global, Inc. “We are happy to report that the Company has maintained its current reporting with OTC Markets and is continuing in its efforts to complete the Company audit needed to once again become and SEC reporting company.”

“Huella Singani embodies a rich culture from Bolivia. We are very excited to be the first to introduce it to the North American and Caribbean markets,” said Nick Coss, Spirits Marketing & Logistics for KRTL International Corp.

About KRTL International Corp.

KRTL International Corp., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC PINK: KRTL), is an organization focused on green technology. In addition, KRTL International is a consulting and distribution company focused on technology and innovations to help greater profitability, social governance, and environmental outcomes to increase and support the 2030 Agenda. This will contribute to improved production, nutritional quality, storage stability, food security, social equity, smart cities, technological advancement for sustainability and much more.

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the OTC Markets Group, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

[budfoxfun]

$CBGL During the second fiscal quarter, the Company announced the successful conclusion of debt settlement negotiations with two debtholders, eliminating approximately $813,000 of long-term debt from the Company’s balance sheet. In April of 2022, the Company entered into a cannabis cultivation joint venture where Cannabis Global issued a note as payment for specific tasks to be completed by the joint venture. Due to rapidly falling prices for cannabis biomass, the cultivation effort never materialized. The parties to the joint venture agreed on terms of the note cancellation to benefit both entities.

“We continue to restructure our balance sheet to create additional value for our shareholders,” commented Edward Manolos, CEO of Cannabis Global. “There is undoubtedly tremendous turmoil in the California cannabis markets, but we continue our commitment to the cannabis marketplace and fully expect to emerge as a more vital organization. This additional $421,000 cancellation will allow us to present a stronger balance sheet to the marketplace and meaningfully further our restructuring program.”

https://www.marketwatch.com/press-release/cannabis-global-files-latest-quarterly-report---receives-additional-debt-cancellations-2023-04-18?mod=mw_quote_news_seemore

[budfoxfun]

$ASRE on alert .20's thinning here! $AGBA $BAOS $TSLA $GDC $ILUS $UTME $WAFU $SNTG $ATXG $IFUS $MDCE $CNNA $FRC $TIRX $HOUR

[Killinit272]

$CAFI NMN Promising Compound


Twitter
https://tinyurl.com/2p9e48zm

[deri21]

$HALB Halberd Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
https://healthstockshub.com/news/otcmkts/halb/halberd-halb-pursuing-a-nasal-spray-to-counteract-the-effects-of-head-trauma

[Robertscott]

$CBGL The Company believes that these debt restructurings and settlements will go a long way to demonstrate to its investors and potential financiers, Cannabis Global’s potential in the California cannabis sector and provide a better position for what the Company’s executives believe, will soon be a true nationwide market for our products and services. These debt reductions will also help reduce future market dilution and help support a healthier market cap and enterprise value.

https://www.barrons.com/articles/cannabis-global-files-latest-quarterly-report-receives-additional-debt-cancellations-f1668406?mod=md_stockoverview_news

[budfoxfun]

$CBGL The Company indicates it has entered into additional debt settlement negotiations aimed at further reducing the Company’s debt burden, which it anticipates will be completed over the next fiscal quarter.

About Cannabis Global, Inc.
Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

[budfoxfun]

$CBGL April 18, 2023 (GLOBE NEWSWIRE) -- Cannabis Global, Inc. (OTC PINK: CBGL), a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, today announces the filing of its quarterly report for the fiscal quarter ending February 28, 2023, and additional debt cancellations designed to strengthen the corporate balance sheet. Cannabis Global remains compliant relative to the reporting requirements for public quoting under Rule 15c2-11.

During the second fiscal quarter, the Company announced the successful conclusion of debt settlement negotiations with two debtholders, eliminating approximately $813,000 of long-term debt from the Company’s balance sheet. In April of 2022, the Company entered into a cannabis cultivation joint venture where Cannabis Global issued a note as payment for specific tasks to be completed by the joint venture. Due to rapidly falling prices for cannabis biomass, the cultivation effort never materialized. The parties to the joint venture agreed on terms of the note cancellation to benefit both entities.

“We continue to restructure our balance sheet to create additional value for our shareholders,” commented Edward Manolos, CEO of Cannabis Global. “There is undoubtedly tremendous turmoil in the California cannabis markets, but we continue our commitment to the cannabis marketplace and fully expect to emerge as a more vital organization. This additional $421,000 cancellation will allow us to present a stronger balance sheet to the marketplace and meaningfully further our restructuring program.”

The Company believes that these debt restructurings and settlements will go a long way to demonstrate to its investors and potential financiers, Cannabis Global’s potential in the California cannabis sector and provide a better position for what the Company’s executives believe, will soon be a true nationwide market for our products and services. These debt reductions will also help reduce future market dilution and help support a healthier market cap and enterprise value.

The Company indicates it has entered into additional debt settlement negotiations aimed at further reducing the Company’s debt burden, which it anticipates will be completed over the next fiscal quarter.

About Cannabis Global, Inc.
Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

[budfoxfun]

$CBGL Cannabis Global is a publicly traded company focused on delivering long-term shareholder growth and results. We invest with confidence and determination to be the forefront of the cannabis and CBD revolution.

https://cannabisglobalinc.com/

[Robertscott]

$CBGL is focused on multiple growing verticals within the global cannabis & CBD industry. This is accomplished through partnerships, acquisitions, and intellectual property.

[budfoxfun]

$CBGL the Company entered into a cannabis cultivation joint venture where Cannabis Global issued a note as payment for specific tasks to be completed by the joint venture. Due to rapidly falling prices for cannabis biomass, the cultivation effort never materialized. The parties to the joint venture agreed on terms of the note cancellation to benefit both entities.

“We continue to restructure our balance sheet to create additional value for our shareholders,” commented Edward Manolos, CEO of Cannabis Global. “There is undoubtedly tremendous turmoil in the California cannabis markets, but we continue our commitment to the cannabis marketplace and fully expect to emerge as a more vital organization. This additional $421,000 cancellation will allow us to present a stronger balance sheet to the marketplace and meaningfully further our restructuring program.”

The Company believes that these debt restructurings and settlements will go a long way to demonstrate to its investors and potential financiers, Cannabis Global’s potential in the California cannabis sector and provide a better position for what the Company’s executives believe, will soon be a true nationwide market for our products and services. These debt reductions will also help reduce future market dilution and help support a healthier market cap and enterprise value.

The Company indicates it has entered into additional debt settlement negotiations aimed at further reducing the Company’s debt burden, which it anticipates will be completed over the next fiscal quarter.

About Cannabis Global, Inc.
Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

[budfoxfun]

$CBGL (GLOBE NEWSWIRE) -- Cannabis Global, Inc. (OTC PINK: CBGL), a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, today announces the filing of its quarterly report for the fiscal quarter ending February 28, 2023, and additional debt cancellations designed to strengthen the corporate balance sheet. Cannabis Global remains compliant relative to the reporting requirements for public quoting under Rule 15c2-11.

During the second fiscal quarter, the Company announced the successful conclusion of debt settlement negotiations with two debtholders, eliminating approximately $813,000 of long-term debt from the Company’s balance sheet. In April of 2022, the Company entered into a cannabis cultivation joint venture where Cannabis Global issued a note as payment for specific tasks to be completed by the joint venture. Due to rapidly falling prices for cannabis biomass, the cultivation effort never materialized. The parties to the joint venture agreed on terms of the note cancellation to benefit both entities.

“We continue to restructure our balance sheet to create additional value for our shareholders,” commented Edward Manolos, CEO of Cannabis Global. “There is undoubtedly tremendous turmoil in the California cannabis markets, but we continue our commitment to the cannabis marketplace and fully expect to emerge as a more vital organization. This additional $421,000 cancellation will allow us to present a stronger balance sheet to the marketplace and meaningfully further our restructuring program.”

The Company believes that these debt restructurings and settlements will go a long way to demonstrate to its investors and potential financiers, Cannabis Global’s potential in the California cannabis sector and provide a better position for what the Company’s executives believe, will soon be a true nationwide market for our products and services. These debt reductions will also help reduce future market dilution and help support a healthier market cap and enterprise value.

The Company indicates it has entered into additional debt settlement negotiations aimed at further reducing the Company’s debt burden, which it anticipates will be completed over the next fiscal quarter.

About Cannabis Global, Inc.
Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

[budfoxfun]

$CBGL During the second fiscal quarter, the Company announced the successful conclusion of debt settlement negotiations with two debtholders, eliminating approximately $813,000 of long-term debt from the Company’s balance sheet. In April of 2022, the Company entered into a cannabis cultivation joint venture where Cannabis Global issued a note as payment for specific tasks to be completed by the joint venture. Due to rapidly falling prices for cannabis biomass, the cultivation effort never materialized. The parties to the joint venture agreed on terms of the note cancellation to benefit both entities.

“We continue to restructure our balance sheet to create additional value for our shareholders,” commented Edward Manolos, CEO of Cannabis Global. “There is undoubtedly tremendous turmoil in the California cannabis markets, but we continue our commitment to the cannabis marketplace and fully expect to emerge as a more vital organization. This additional $421,000 cancellation will allow us to present a stronger balance sheet to the marketplace and meaningfully further our restructuring program.”

https://www.marketwatch.com/press-release/cannabis-global-files-latest-quarterly-report---receives-additional-debt-cancellations-2023-04-18?mod=mw_quote_news_seemore

[Golden Cross]

$AVOI Early here--8K Change of control filed 4-24... I think we see something very nice come into AVOI... New owner has million$ and many business contacts I am looking into. Stay tuned.... More to come....

[Robertscott]

$EMED The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

[budfoxfun]

$EMED Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$SGTM The Sustainable Green Team, LTD. Upgrades its Mulch Colorant Division to a Larger State of the Art Facility to Increase Production Due to Increase Demand https://finance.yahoo.com/news/sustainable-green-team-ltd-upgrades-132400465.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[Robertscott]

$EMED Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations

https://finance.yahoo.com/news/electromedical-technologies-announces-preliminary-unaudited-121900011.html

[budfoxfun]

$EMED Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED SCOTTSDALE, Ariz., March 14, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

[deri21]

$HRAL HearAtLast Holdings, Inc (OTC:HRAL) Introduces New Company Website
https://www.accesswire.com/751221/HearAtLast-Holdings-Inc-OTCHRAL-Introduces-New-Company-Website

[Robertscott]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[deri21]

$BLQC BlockQuarry Announces 2022 Annual Financial Report with a 520% YOY Increase in Revenues
https://www.globenewswire.com/news-release/2023/04/26/2654986/0/en/BlockQuarry-Announces-2022-Annual-Financial-Report-with-a-520-YOY-Increase-in-Revenues.html

[budfoxfun]

$EMED is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED during the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$SOBR big news last week: Fox Group Intends to Drive SOBRsafe Adoption in Oil and Gas, Mining and Trucking https://finance.yahoo.com/news/fox-group-intends-drive-sobrsafe-120000283.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[budfoxfun]

$EMED The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[Robertscott]

$EMED
The WellnessPro Plus®

triggers our body’s natural processes. Electrical impulses travel from nerves around the injured area to our brain, delivering the unpleasant sensation of pain. WellnessPro Plus® operates by disrupting these pain signals received by our synapses, mimicking our natural electric signals to relieve patients from pain.

Electromedical Technologies brought together some of the leading biomedical researchers from around the world to develop next generation TENS machines. Through product innovation and a forward-thinking approach, we succeeded to develop specific algorithms in electrotherapy that work to alleviate pain.

[budfoxfun]

$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.

[budfoxfun]

$EMED Electricity enables information to circulate in the body, electrotherapy manipulates a specific part of the information by pulsating electrical waves interfering with the transmission of pain signals.
Our nervous system is composed of our brain and our spinal cord, which combine to form the central nervous system; and our sensory and motor nerves, which form the peripheral nervous system. Nerves send information about what is happening in our environment to the brain via the spinal cord. The brain then sends information back to our nerves, helping us to perform actions in response. By treating specific body areas and varying frequency, wavelength and intensity applied, electrotherapy devices can manipulate impulses and target actions to alleviate pain or they can disrupt pain signals.

[Robertscott]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[Killinit272]

Enters $5 Trillion Industry

Big news from CAFI! The company has just announced its entry into the $5 trillion sports nutrition and health and wellness industries. Exciting times ahead for CAFI and its customers. #health #wellness #sportsnutrition@brandonspikes55 https://t.co/UVKZnTUig8

— Fifty 1 Labs $CAFI (@Fifty1Labs) April 24, 2023

$CAFI

[budfoxfun]

$EMED News: SCOTTSDALE, Ariz., March 14, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED their management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

[budfoxfun]

$EMED With over a million frequencies to choose from, WellnessPro Plus® offers the widest frequency range on the market allowing it to have numerous applications. FDA CLEARED, it features a “future-ready” modular design, making it widely adaptable to new accessories and therapies.

[budfoxfun]

$EMED Electromedical’s commitment to create long-lasting drug-free solutions to pain management is honored by the development of The WellnessPro Plus®, a technologically advanced TENS (transcutaneous electrical nerve stimulation) therapy device focusing on pain relief.

[deri21]

$PBIO Pressure BioSciences Unveils Powerful THC Market Leapfrog Opportunity with Exclusive Licensing of Their Revolutionary UltraShear Nanoemulsion Processing Platform
https://www.accesswire.com/750615/Pressure-BioSciences-Unveils-Powerful-THC-Market-Leapfrog-Opportunity-with-Exclusive-Licensing-of-Their-Revolutionary-UltraShear-Nanoemulsion-Processing-Platform

[AyaStocks]

CapitalGainsReport: OTC Momentum Watchlist ($EPAZ, $GTCH, $TSOI, $SIRC) https://www.marketscreener.com/quote/stock/EPAZZ-INC-111313555/news/CapitalGainsReport-OTC-Momentum-Watchlist-EPAZ-GTCH-TSOI-SIRC-43599020/

[budfoxfun]

$EMED Electricity enables information to circulate in the body, electrotherapy manipulates a specific part of the information by pulsating electrical waves interfering with the transmission of pain signals.
Our nervous system is composed of our brain and our spinal cord, which combine to form the central nervous system; and our sensory and motor nerves, which form the peripheral nervous system. Nerves send information about what is happening in our environment to the brain via the spinal cord. The brain then sends information back to our nerves, helping us to perform actions in response. By treating specific body areas and varying frequency, wavelength and intensity applied, electrotherapy devices can manipulate impulses and target actions to alleviate pain or they can disrupt pain signals.